SciSparc Subsidiary NeuroThera Acquires Quantum Clinical Trials Firm, Parent's Stake Diluted
SPRC sits 17% above its 52-week low of $3.6 on elevated volume (19× avg).
Summary
SciSparc's majority-owned subsidiary, NeuroThera Labs, is acquiring a 54% stake in CliniQuantum for approximately $9.46 million in NeuroThera shares, which will dilute SciSparc's ownership in NeuroThera from 75% to 43.86%. Additionally, NeuroThera announced a new international patent application for a weight loss and fatty liver disease therapy.
Key Events · M&A and Partnerships · SPRC
-
Subsidiary Acquires Quantum Clinical Trials Firm
SciSparc's majority-owned subsidiary, NeuroThera Labs Inc., is acquiring a 54.01% stake in CliniQuantum Ltd., an innovator in quantum-based clinical trials. The initial consideration is approximately $9.46 million in NeuroThera common shares, with potential earn-out payments of up to $2.5 million.
-
Parent Company's Stake in Subsidiary Diluted
Following the acquisition, SciSparc's ownership interest in NeuroThera Labs is expected to decrease significantly from approximately 75% to 43.86%.
-
New Patent for Weight Loss and Fatty Liver Disease Therapy
NeuroThera Labs announced the publication of an international patent application, in collaboration with Clearmind Medicine, for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).
Analysis · SPRC · Life Sciences
This 6-K filing details a significant strategic move by SciSparc's subsidiary, NeuroThera Labs, to acquire CliniQuantum, a quantum technology company focused on clinical trials. The acquisition, valued at approximately $9.46 million initially, represents a substantial investment relative to SciSparc's market capitalization. While strategically positive for NeuroThera's growth into innovative clinical trial technologies, it will significantly dilute SciSparc's controlling interest in NeuroThera from 75% to 43.86%. Investors should monitor the integration of CliniQuantum and the performance of NeuroThera post-acquisition, as well as the progress of the newly patented therapy for weight loss and fatty liver disease.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.9% of the 1728 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.06%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRC was trading at $4.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $3.60 to $94.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.